589 related articles for article (PubMed ID: 19667635)
1. Achieving cholesterol goals. Current and future drug therapies.
Jones PH
Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
[TBL] [Abstract][Full Text] [Related]
2. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
4. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
5. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Ballantyne CM
Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
[TBL] [Abstract][Full Text] [Related]
6. Statins, super-statins and cholesterol absorption inhibitors.
Brousseau ME
IDrugs; 2003 May; 6(5):458-63. PubMed ID: 12789600
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
8. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
9. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
10. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Kastelein JJ
Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
[TBL] [Abstract][Full Text] [Related]
11. CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management.
Thompson PD
Postgrad Med; 2003 Aug; 114(2 Suppl):22-30. PubMed ID: 19667636
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of multidrug therapy to achieve lipid goals.
Denke MA
J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S17-22. PubMed ID: 15467020
[TBL] [Abstract][Full Text] [Related]
14. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
15. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
16. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol and coronary events. The current thinking.
Jones PH
Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
[TBL] [Abstract][Full Text] [Related]
18. Treating dyslipidemia in the high-risk patient.
Jones PH
J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
[TBL] [Abstract][Full Text] [Related]
19. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
[TBL] [Abstract][Full Text] [Related]
20. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Vaverková H
Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]